RPL23A and colorectal carcinoma: Among the most promising Combi targets are moderately characterized proteins, such as NPM1, VCP, CCT3, SNRPN, BOP1, SYNCRIP, EIF1, and RPS27A, poorly characterized proteins in the CRC context, including NIFK, UBA52, CCT7, RANBP2, RPL23A, and RPS15, as well as newly identified proteins such as UBB, UBC, RPS16, RPS13, RPL23, and GFM1 (Figure 7e and Table 1).